梁颕宇女士是启明创投的主管合伙人，领导医疗健康行业投资。启明创投是中国最活跃的创投基金公司之一，目前投资了超过430家创新企业。

加入启明创投前，梁女士是生原控股有限公司的合伙创始人。该公司主要在中国运营和投资有关医疗仪器、药品和医疗保健服务的公司，其中包括专门研究肿瘤和中枢神经系统的诺凡麦医药（上海）有限公司（被赛生药业收购，NASDAQ：SCLN）、U-Systems Inc (被通用电气医疗集团收购)。另外，梁女士亦曾于美国加州PacRim风险投资公司担任投资合伙人，及曾就职于Softbank/Mobius 风险投资公司。

梁女士在福布斯2019、2020和2021年度全球最佳创投人榜中占一席位。她也被福布斯中国评选为2021中国最佳女性创投人Top 2，2018中国最佳女性创投人Top 3以及被Asian Venture Capital Journal评选为AVCJ 2017年度创业投资人士奖。

梁女士于斯坦福大学商学院和康奈尔大学分别获得工商管理硕士学位及管理学学士学位。目前，她是哈佛大学法律学院的客座讲师、斯坦福大学商学院顾问委员会委员、香港交易所独立非执行董事及香港故宫文化博物馆董事局成员。

Nisa Leung is Managing Partner of Qiming Venture Partners, leading its health care investments. Qiming Venture Partners is a leading investment firm in China which currently manages investment in over 380 companies.

Prior to joining Qiming, she was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including Novamed Pharmaceuticals (acquired by SciClone NASDAQ:SCLN) and U-Systems (acquired by GE Healthcare).  Nisa was Venture Partner of PacRim Ventures in Menlo Park, and was previously with Softbank/Mobius Venture Capital.

Nisa has been recognized by the Forbes Global 100 VC Midas List in 2019, 2020 and 2021, named Best Women VCs List by Forbes China (#2 in 2021, #3 in 2018) and won Venture Capital Professional of the Year by Asian Venture Capital Journal in 2017.

Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently visiting lecturer at Harvard Law School, member of Stanford Graduate School of Business Advisory Council and serves as an independent non-executive director of the Hong Kong Exchanges and Clearing Limited (“HKEX”) and Hong Kong Palace Museum.